Although anti-PD-1/PD-L1 immunotherapy has revolutionized the field of cancer treatment in multiple tumor types, only a small subset of patients benefits from such therapies, partially due to the “coldness” of the tumors, characterized by limited infiltration of lymphocytes (TILs) 31, particularly cytotoxic T cells. The gene discussed is CD274; the disease is cancer.